Author: Topher McCulloch

TUCSON, Ariz., November 15, 2022 — The Critical Path for Alzheimer’s Disease (CPAD) at the Critical Path Institute (C-Path) and Cerveau Technologies, Inc. are proud to announce a data sharing collaboration to advance the scientific understanding of disease pathology and progression and enable development of novel quantitative Drug Development Tools in Alzheimer’s disease (AD) and related dementias.

Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam® Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

A new positron emission tomography radiotracer has the potential to spot signs of Alzheimer’s disease years before symptoms appear.

That’s according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, which wraps up on Tuesday, June 15. The chemical compound 18F-MK6240 has been shown to effectively measure increases in brain tau, a protein commonly found in healthy brain neurons.

Scientists see potential in using the new tracer to test the impact of emerging Alzheimer’s therapies. Read More

CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain.  Read More

Cerveau Technologies, Inc. today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.

MK-6240 Users Group Meeting | Webinar #1 by Cerveau Technologies Inc
2020 Virtual Conference with world renowned Leaders and Scientists in the industry!

Rick Hiatt (Cerveau Technologies)
Oskar Hannson (Lund University)
Pedro Rosa-Neto (McGill University)
Keith Johnson (Harvard University)
Kuang Gong (Harvard University)
Christopher Rowe (University of Melbourne)
See the conference here

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

TORONTO–(BUSINESS WIRE)–Enigma Biomedical Group (EBG) today announced the appointment of Michael Reitermann to their Board of Directors effective December 1, 2019

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the Kobe City Hospital Organisation in Japan to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with the University of Washington to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.